Cell Therapy for Non-Small Cell Lung Cancer is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cell Therapy for Non-Small Cell Lung Cancer’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cell Therapy for Non-Small Cell Lung Cancer overview
Cell therapy is under development for the treatment of non-small cell lung cancer. It is administered through parenteral route. The therapy comprises autologous natural killer cells (NK cells) and gamma delta T cells (gdT cells).
For a complete picture of Cell Therapy for Non-Small Cell Lung Cancer’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.